Atlas Trials

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Clinical trial NCT01215136 · TERMINATED

Trial details

NCT number
NCT01215136
Sponsor
Matthew Galsky
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Transitional Cell CarcinomaBladder CarcinomaUrothelial Carcinoma
Start date
2010-12-01
Primary completion
2017-04-24
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.